London: A radioactive "paste" could cure skin cancer in just two hours, say researchers.
It can destroy tumours caused by skin cancers without surgery or conventional radiotherapy.
The treatment, however, is not suitable for malignant melanoma, the deadliest form of skin cancer.
Experts say there are minimal side effects and the treatment does not even leave a scar, the Daily Mail reported Friday.
The breakthrough therapy, which has been used on 700 patients in Italy with a success rate of up to 95 percent, could be available in Britain within two years.
The new technique can treat basal cell carcinoma and squamous cell carcinoma. These cancers affect 100,000 people in Britain every year, the newspaper said.
The vast majority of those who suffer the less dangerous forms have surgery to remove the affected tissue.
Other treatments include radiotherapy and "freezing" of the tumours if they are small and superficial.
But an estimated three percent of patients have deep tumours that are difficult to remove surgically because they are on sensitive areas such as the eyes, nose or ears. Others cannot have surgery due to age or medical conditions.
These patients are given radiotherapy that often results in serious side-effects.
For the new technique, Italian researchers harnessed rhenium-188, a radioactive isotope that was previously rare and expensive.
But now it is being supplied in quantities large enough to treat thousands of patients a week by nuclear physicists at the British-funded Institut Laue-Langevin in France.
The treatment, which is said to be painless, involves putting a piece of surgical foil on the tumour area, painting on the radioactive paste and removing it one or two hours later.
Researchers believe that the radiation causes healthy skin to re-grow, so there is no scarring.
In the Italian trial, 85 percent of patients were cured after one treatment and up to 95 percent after three treatments.
Oliver Buck, chief executive of the German technology firm ITM which developed the therapy, said: "This means that patients with large and difficult-to-treat tumours not only have hope but keep their quality of life under what would otherwise be dire conditions."
Trials are now being held in Germany and Australia, and Buck believes the treatment could be licensed in Britain within two years.
IANS
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookies Setting
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device and the processing of information obtained via those cookies (including about your preferences, device and online activity) by us and our commercial partners to enhance site navigation, personalise ads, analyze site usage, and assist in our marketing efforts. More information can be found in our Cookies and Privacy Policy. You can amend your cookie settings to reject non-essential cookies by clicking Cookie Settings below.
Manage Consent Preferences
Strictly Necessary Cookies
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work or you may not be able to login.
Functional Cookies
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They are also used to limit the number of times you see an advert as well as help measure the effectiveness of an advertising campaign. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we may not know when you have visited our site, and may not be able to monitor its performance.